ARWR – Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.

ARWR

$14.91

Name : Arrowhead Pharmaceuticals, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $2,059,070,976.00

EPSttm : -5.15

Arrowhead Pharmaceuticals, Inc.

$14.91

2.42%

$0.37

Float Short %

11.83

Margin Of Safety %

Put/Call OI Ratio

1.15

EPS Next Q Diff

EPS Last/This Y

1.68

EPS This/Next Y

-0.51

Price

14.9

Target Price

42.31

Analyst Recom

1.62

Performance Q

-19.71

Relative Volume

1.38

Beta

0.95

Ticker: ARWR

23 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-04-14	ARWR	12.33	0.58	0.65	15568
2025-04-15	ARWR	12.85	0.58	0.14	15731
2025-04-16	ARWR	11.34	0.57	0.02	16079
2025-04-17	ARWR	11.22	0.50	0.05	17028
2025-04-18	ARWR	11.24	0.50	0.04	17028
2025-04-21	ARWR	12.07	0.51	21.63	14758
2025-04-22	ARWR	12.35	1.28	0.04	22711
2025-04-23	ARWR	13.01	1.26	0.09	22931
2025-04-24	ARWR	13.32	1.22	0.89	23258
2025-04-25	ARWR	13.25	1.2229131335971	0.289592760181	23594
2025-04-28	ARWR	13.52	1.2163371876166	0.7469512195122	23768
2025-04-29	ARWR	13.48	1.20	0.23	24127
2025-04-30	ARWR	13.89	1.17	5.23	24513
2025-05-01	ARWR	14.03	1.52	0.38	30416
2025-05-02	ARWR	14.41	1.47	0.45	31445
2025-05-05	ARWR	13.98	1.45	0.03	31972
2025-05-06	ARWR	13.06	1.22	0.89	34608
2025-05-07	ARWR	13.05	1.22	0.33	35046
2025-05-08	ARWR	13.24	1.21	1.00	35334
2025-05-09	ARWR	13.03	1.22	1.08	35651
2025-05-12	ARWR	13.97	1.22	0.11	36275
2025-05-13	ARWR	15.29	1.20	0.12	36682
2025-05-14	ARWR	14.91	1.15	0.23	37501
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

23 items 1 of 1

23 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-04-14	ARWR	12.34	54.7	327.7	-3.32
2025-04-15	ARWR	12.87	54.7	328.6	-3.32
2025-04-16	ARWR	11.35	54.7	371.1	-3.32
2025-04-17	ARWR	11.24	54.7	342.5	-3.32
2025-04-18	ARWR	11.24	54.7	339.9	-3.32
2025-04-21	ARWR	12.07	54.7	320.4	-3.32
2025-04-22	ARWR	12.36	54.7	333.9	-3.32
2025-04-23	ARWR	13.01	54.7	326.0	-3.32
2025-04-24	ARWR	13.35	54.7	333.0	-3.32
2025-04-25	ARWR	13.25	54.7	341.8	-3.32
2025-04-28	ARWR	13.52	54.7	334.6	-3.32
2025-04-29	ARWR	13.47	54.7	340.9	-3.32
2025-04-30	ARWR	13.87	54.7	332.1	-3.32
2025-05-01	ARWR	14.03	54.7	336.9	-3.32
2025-05-02	ARWR	14.42	54.7	332.9	-3.32
2025-05-05	ARWR	13.97	54.7	348.1	-3.32
2025-05-06	ARWR	13.06	54.7	357.3	-3.32
2025-05-07	ARWR	13.06	54.7	340.3	-3.32
2025-05-08	ARWR	13.23	54.7	336.5	-3.32
2025-05-09	ARWR	13.02	54.7	344.5	-3.32
2025-05-12	ARWR	13.97	54.7	320.9	-3.32
2025-05-13	ARWR	15.29	54.7	315.0	-3.32
2025-05-14	ARWR	14.90	54.7	346.6	-3.32
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

23 items 1 of 1

23 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-04-14	ARWR	-2.87	2.96	10.49
2025-04-15	ARWR	-2.87	2.96	10.49
2025-04-16	ARWR	-2.87	2.96	10.49
2025-04-17	ARWR	-2.87	2.96	10.49
2025-04-18	ARWR	-2.87	2.96	10.48
2025-04-21	ARWR	-2.87	3.23	10.48
2025-04-22	ARWR	-2.89	3.23	10.48
2025-04-23	ARWR	-2.89	3.23	10.48
2025-04-24	ARWR	-2.89	3.23	10.48
2025-04-25	ARWR	-2.89	3.23	10.48
2025-04-28	ARWR	-2.89	3.03	10.96
2025-04-29	ARWR	-2.89	3.03	10.96
2025-04-30	ARWR	-2.89	3.03	10.96
2025-05-01	ARWR	-2.89	3.03	10.96
2025-05-02	ARWR	-2.89	3.03	10.96
2025-05-05	ARWR	-2.89	6.09	10.96
2025-05-06	ARWR	-2.89	6.09	10.96
2025-05-07	ARWR	-2.89	6.09	10.96
2025-05-08	ARWR	-2.89	6.09	10.96
2025-05-09	ARWR	-2.89	6.09	10.96
2025-05-12	ARWR	-2.89	7.43	11.83
2025-05-13	ARWR	-2.89	7.43	11.83
2025-05-14	ARWR	-2.89	7.43	11.83
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

23 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.46

Avg. EPS Est. Next Quarter

-0.94

Insider Transactions

-2.89

Institutional Transactions

7.43

Beta

0.95

Average Sales Estimate Current Quarter

116

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

84.1

Max Drawdown 5-Year %

-89

Target Price

42.31

P/E

Forward P/E

PEG

P/S

3.78

P/B

3.01

P/Free Cash Flow

447.62

EPS

-1.38

Average EPS Est. Cur. Y

-3.32

EPS Next Y. (Est.)

-3.83

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-26.41

Relative Volume

1.38

Return on Equity vs Sector %

-1240.1

Return on Equity vs Industry %

-1223.3

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.28

EBIT Estimation

346.6

Arrowhead Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 609

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.

stock quote shares ARWR – Arrowhead Pharmaceuticals, Inc. Stock Price stock today

news today ARWR – Arrowhead Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch ARWR – Arrowhead Pharmaceuticals, Inc. yahoo finance google finance

stock history ARWR – Arrowhead Pharmaceuticals, Inc. invest stock market

stock prices ARWR premarket after hours

ticker ARWR fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

ARWR – Arrowhead Pharmaceuticals, Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ARWR

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y